Eurofins Enhances Its Clinical and BioPharma Service Offering in Japan with Immune Repertoire Analysis Technology Through the Acquisition of Repertoire Genesis Inc.
businesswire.com
news
2022-05-31 00:00:00

May 31, 2022 01:15 AM Eastern Daylight Time LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:

Eurofins Scientific (Paris:ERF) (EUFI.PA), a global scientific leader in bioanalytical testing and clinical diagnostics testing, announces the completion of the acquisition of a majority stake in Repertoire Genesis Inc. ('RG'). RG owns a unique and proprietary analytical platform, TCR/BCR (T Cell Receptor/B Cell Receptor) repertoire profiling, that enables scientists to determine the specific pathophysiological status of immune responses derived from cancer, autoimmune diseases, transplants, and infectious diseases.
